There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
NCT06878261
Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
07/23/2025
Locations: Research Site, Houston, Texas
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
NCT06846515
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Arthrosi Investigative Site (601), Houston, Texas
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
Register for Updates
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
NCT05320198
Recruiting
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis or myelodysplastic syndrome and anemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: MD Anderson, Houston, Texas
Conditions: Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Myelodysplastic Syndromes
Register for Updates
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT05417594
Recruiting
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/23/2025
Locations: Research Site, Houston, Texas
Conditions: Advanced Solid Malignancies
Register for Updates
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
NCT05479812
Recruiting
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: NEXT Oncology, Houston, Texas
Conditions: Metastatic Solid Tumor, Advanced Solid Tumor
Register for Updates
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168
Recruiting
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/23/2025
Locations: Research Site, Houston, Texas
Conditions: Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer
Register for Updates
QTX3034 in Patients With KRAS G12D Mutation
NCT06227377
Recruiting
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: MD Anderson, Houston, Texas
Conditions: Solid Tumors
Register for Updates
A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
NCT06422520
Recruiting
This is a first-in-human, Phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of BGB-C354 alone and in combination with tislelizumab in participants with advanced solid tumors. Study details include: * The study will be conducted in 2 phases: Phase 1a (Monotherapy Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion). * The visit frequency will be approximately every 21 days during study treatment. Maximum treatment duratio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: The University of Texas Md Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor
Register for Updates
A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT06655246
Recruiting
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: University of Texas, Houston, Texas
Conditions: Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Tumor (GIST) of the Gastrointestinal Tract, Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors
Register for Updates
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
NCT07000123
Recruiting
This is a study to evaluate the efficacy and safety of AZD0780 in adults with clinical ASCVD or who are at risk for a first ASCVD event and who have elevated LDL-C. AZD0780 is a small molecule that reduces the amount of LDL-C in the blood. Placebo will be used for comparison, and neither the participants nor the Investigators will know who is receiving the AZD0780 medication and who is receiving the placebo until the end of study. The total length of the study for an individual participant will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Research Site, Houston, Texas
Conditions: Cardiovascular Disease
Register for Updates
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
NCT06685718
Recruiting
This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation targeted Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung Cancer (NSCLC). This study will evaluate how well BG-60366 works in participants with advanced or metastatic EGFR-mutant NS... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: The University of Texas Md Anderson Cancer Center, Houston, Texas
Conditions: Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), EGFR Activating Mutation, EGFR Mutation-Related Tumors
Register for Updates
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
NCT06739122
Recruiting
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/22/2025
Locations: Texas Childrens Hospital, Houston, Texas
Conditions: Type 2 Diabetes
Register for Updates